Skip to main content

hyaluronidase

Generic: hyaluronidase·Brand: Hylenex, Rituxan Hycela

hyaluronidase: 3 clinical trials tracked.

hyaluronidase evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about hyaluronidase, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (3)

A Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Chinese Adult Male Subjects

NCT07484893Registry updated 2026-03-20·Phase 1
Not yet recruiting

Primary endpoint: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen24 targetStarted 2026-05Completion 2026-101 site · ChinaShanghai Henlius Biotech

A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ)

NCT07161414Registry updated 2026-10-05·Phase 1·AZN
Recruiting

Primary endpoint: Area under the Concentration-time Curve During One Dosing Interval (AUCtau)

InterventionalRandomizedopen40 targetStarted 2025-11Completion 2029-0711 sites · South Korea, Spain, United Kingdom, United StatesAstraZeneca

A Phase 1, Open-Label, Single Center, Dose Escalation Study of the Safety and Pharmacokinetics of mAb AZD5396 and mAb AZD8076 Delivered as dMAbs in Healthy Adults

NCT05293249Registry updated 2026-01-22·Phase 1
Completed

Primary endpoint: Frequency and nature of injection site reaction

Interventionalopen61 enrolledStarted 2022-05Completion 2025-111 site · United StatesPablo Tebas